RxDoctor Payments Data

Sierra Palochak, PA

Physician Assistant · Reading, PANPI 1114410602

Payments from drug & device makers

$1,999in general payments, 2019–2025

Across 102 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$515
  • E.r. Squibb & Sons, L.L.C.$349
  • Abbott$243
  • Johnson & Johnson$180
  • AstraZeneca$140
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$124
  • plus $447 from 9 others

What the payments were for

  • Food & beverage$1,999100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,999 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$68,997
Medicare patients
523
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban601$587,118
XareltoRivaroxaban80$84,761
Repatha SureclickEvolocumab101$74,448
EntrestoSacubitril/Valsartan57$64,388
Praluent PenAlirocumab37$22,818
FarxigaDapagliflozin Propanediol29$22,813
Metoprolol Succinate506$7,771
Diltiazem 24hr Er (Cd)Diltiazem Hcl129$3,811
Ezetimibe156$3,791
Amiodarone Hcl97$3,252
Atorvastatin Calcium299$3,240
Ranolazine ErRanolazine29$2,498
Losartan Potassium262$2,241
Metoprolol Tartrate327$2,160
Flecainide Acetate36$2,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$515$587,118601 claims
Johnson & JohnsonXarelto$180$84,76180 claims
NovartisEntresto$82$64,38857 claims
AstraZenecaFarxiga$140$22,81329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →